Citigroup analyst Vivek Agrawal upgrades Dr Reddy's Laboratories (NYSE:RDY) from Sell to Buy

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

Dr Reddy's ​Laboratories ‌said on ​Friday ​it signed a ⁠deal ​with ​Takeda Pharmaceutical Company ​f

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

Dr Reddy's Laboratories (NYSE:RDY) held its first-quarter earnings conference call on Wednesday.

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laborato

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, to

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder righ

Law Offices of Howard G. Smith announces an investigation on behalf of Dr. Reddy's Laboratories (“

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Dr. Red

The law firm of [url="]Kirby McInerney LLP[/url] reminds investors of its investigation on behalf of

NEW YORK--(BUSINESS WIRE)---- $RDY #classactionlawsuit--The law firm of Kirby McInerney LLP reminds

Arrowstreet Capital Limited Partnership purchased a new position in Dr. Reddy's Laboratories Ltd (NY

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating pot

Dr. Reddy's (RDY) stock drops after missing Q1 FY27 earnings & revenue estimates. Semaglutid

Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.06 per share which missed t

Companies Reporting Before The Bell • Northern Trust (NASDAQ:NTRS) is expected to report quarterly e

Dr Reddy's Laboratories (NYSE:RDY) released fourth-quarter financial results and hosted an earni

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that

The launch follows Dr. Reddy's receipt of the Notice of Compliance (NOC) from Health Canada on A

Dr. Reddy's launched generic Semaglutide Injection in Canada, expanding its GLP-1 portfolio and

Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.03 per share which missed t

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with

https://www.bloomberg.com/news/articles/2026-04-28/canada-approves-its-first-generic-version-of-novo

https://www.sec.gov/Archives/edgar/data/1135951/000157587226000247/rdy0885_6k.htm

India's drugmakers roll out low-cost copies for Novo Nordisk's semaglutide, slashing prices

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with

https://www.reuters.com/business/healthcare-pharmaceuticals/dr-reddys-aims-launch-generic-obesity-dr

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage b

Dr Reddy's Laboratories (NYSE:RDY) reported quarterly earnings of $0.16 per share which met the

https://www.bloomberg.com/news/articles/2026-01-21/dr-reddy-s-to-start-selling-generic-ozempic-in-in

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, along with its subsidiaries

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)Regulati

FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving dec

    On Monday, 524 stocks hit new 52-week lows.

    On Friday, 368 stocks hit new 52-week lows.

    Before 10 a.m. ET Friday, 146 stocks hit new 52-week highs.

    This morning 158 companies set new 52-week highs.